Nagano, Japan

Ken Kanada

This inventor holds 3 USPTO granted patents. Top assignee: Kissei Pharmaceutical Co., Ltd.. Active years: 2007.


Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2007

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Ken Kanada: Innovator in Medicinal Compositions

Introduction

Ken Kanada is a notable inventor based in Nagano, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of medicinal compositions. With a total of 3 patents to his name, Kanada's work focuses on innovative solutions for health-related issues.

Latest Patents

Among his latest patents, Kanada has developed immediate release medicinal compositions for oral use. This invention relates to an oral pharmaceutical composition that includes as an active ingredient a calcium salt of a benzylsuccinic acid derivative. This composition is particularly useful as an agent for the treatment of diabetes. The innovative approach taken by Kanada in this area showcases his commitment to improving patient care through effective medication.

Career Highlights

Ken Kanada is associated with Kissei Pharmaceutical Co., Ltd., where he continues to work on advancing pharmaceutical technologies. His role at the company allows him to collaborate with other talented professionals in the field, contributing to the development of new and effective medicinal products.

Collaborations

Some of his notable coworkers include Kiyohisa Ouchi and Kaoru Kaneko. Their collaborative efforts have likely played a role in the successful development of Kanada's patents and innovations.

Conclusion

Ken Kanada's contributions to the pharmaceutical industry through his innovative patents demonstrate his dedication to improving health outcomes. His work continues to influence the development of effective treatments for diabetes and other health conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…